CardioFocus Treats First Patients with Pulsed Field Ablation
CardioFocus, Inc. has initiated the VISION AF clinical trial, marking the first use of its investigational OptiShotâ„¢ Pulsed Field...
Jon Napitupulu
Protein Helps Cancer Evade CAR T-Cell Therapy
Scientists at City of Hope have identified a protein, YTHDF2, that helps blood cancer cells evade CAR T cell...
eClinical Solutions and Snowflake Partner for Life Sciences
eClinical Solutions and Snowflake have partnered to integrate eClinical’s elluminate Clinical Data Cloud with the Snowflake AI Data Cloud....
Silexion’s Precision Oncology Collaboration: Targeting KRAS
Silexion Therapeutics is developing SIL-204, a next-generation siRNA therapy targeting a broad range of KRAS mutations prevalent in difficult-to-treat...
Fresenius Kabi Launches Epinephrine Injection, Expands US Pharma Portfolio
Fresenius Kabi has launched Epinephrine Injection, USP, the first generic version of epinephrine in a 1mg/1mL vial, in the...
Trodelvy Gets Breakthrough Therapy for Lung Cancer
The FDA has granted Breakthrough Therapy Designation to Gilead Sciences’ Trodelvy for treating extensive-stage small cell lung cancerlung cancer...
Naropa University and Center for Psychedelic Studies Separate
Naropa University’s Center for Psychedelic Studies has become an independent entity, the Memoru Center for Visionary Healing Arts, in...
Lerodalcibep Biologic License Application Submitted to FDA
LIB Therapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for Lerodalcibep, a novel PCSK9 inhibitor...
Contineum PIPE-791 Phase 1b PET Trial Begins Patient Dosing
Contineum Therapeutics has initiated a Phase 1b positron emission tomography (PET) trial for PIPE-791, a novel brain-penetrant, small molecule...
Beigene’s Global MAT2A Inhibitor Licensing Deal
BeiGene, soon to be BeOne Medicines, has secured global licensing rights for SYH2039, a novel MAT2A inhibitor, from CSPC....